CD8A and neoplasm: Notably, only the HHD mice receiving both m1G4 CD8 +T cells and rVV NY-ESO-1 9V vaccination showed significant tumor clearance with 4/5 mice tumor free on day 37 (p=0.02), while none of the other tumor groups were statistically different from no cells/no infection—indicating that any variation seen was likely due to inherent immunogenicity of the NY-ESO-1-expressing MCA tumor (1F4), which primed the mouse’s endogenous T-cell repertoire against the foreign NY-ESO-1 antigen.